For $3bn J&J holds on to Halda
The private biotech adds another asset to J&J’s prostate cancer pipeline.
Mersana gets its rescue bid
But the Day One deal is still 29% below where the shares stood at the start of this year.
Lyell shuffles the pipeline again
After more discontinuations, a new deal brings in fresh blood.
Venture capitalists buy into TROP2
Blackstone follows Abingworth, but why?
A cautionary tale for clinical trial collaborators
AstraZeneca ended a tie-up with Asher, and then set off on its own.
Ipsen sees a future in gammadelta T-cells
The company will acquire ImCheck for €350m.
Bispecific cytokine delivers for Innovent at last
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
